In The Star's annual year in review, the county's biggest business stories included housing proposals and the aftermath of a ...

On December 19, 2025, the National Security Commission on Emerging Biotechnology (NSCEB) announced the publication of a paper entitled “The Future of U.S.-China Biotechnology Competition.” The paper ...

It took 27 years, but Cytokinetics secured its first U.S. drug approval. On Friday, the Food and Drug Administration cleared ...

An announcement from Anbio Biotechnology Class A ( ($NNNN) ) is now available. On December 30, 2025, Anbio Biotechnology reported unaudited ...

Adding another potential wrinkle to the industry’s work with China is the Biosecure Act, a piece of China-targeting national ...

After a strong biotech rebound, one fund quietly walked away from sector beta, and the timing says more than the trade itself.

Norgine, a leading European specialty pharmaceutical company, today announced an exclusive licensing agreement under which ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Beijing has repeatedly shown the world that it is willing to weaponize its dominance of supply chains, and President Donald Trump had to de-escalate the latest rare-earth dispute during his recent ...

Discover how intellectual property rights protect exclusive pharmaceutical use and brand names in biotechnology, influencing innovation and market dynamics.